Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$265.98
-2.5%
$267.42
$199.90
▼
$290.25
$640.46B0.227.95 million shs6.02 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,353.51
-2.1%
$1,258.86
$850.51
▼
$1,475.25
$1.27T0.42.95 million shs1.89 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,353.51
-2.1%
$1,258.86
$850.51
▼
$1,475.25
$1.27T0.42.95 million shs1.89 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$38.68
-1.9%
$39.79
$35.12
▼
$64.16
$172.84B0.716.31 million shs11.27 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-2.04%-2.77%+7.38%+1.75%+36.30%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.25%-3.93%+11.12%+10.75%+34.01%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.25%-3.93%+11.12%+10.75%+34.01%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.85%-3.99%+2.89%-14.71%-16.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$265.98
-2.5%
$267.42
$199.90
▼
$290.25
$640.46B0.227.95 million shs6.02 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,353.51
-2.1%
$1,258.86
$850.51
▼
$1,475.25
$1.27T0.42.95 million shs1.89 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,353.51
-2.1%
$1,258.86
$850.51
▼
$1,475.25
$1.27T0.42.95 million shs1.89 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$38.68
-1.9%
$39.79
$35.12
▼
$64.16
$172.84B0.716.31 million shs11.27 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-2.04%-2.77%+7.38%+1.75%+36.30%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.25%-3.93%+11.12%+10.75%+34.01%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-2.25%-3.93%+11.12%+10.75%+34.01%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
-2.85%-3.99%+2.89%-14.71%-16.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.73
Moderate Buy$275.923.74% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,422.005.06% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,422.005.06% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.00
Hold$59.4453.67% Upside

Current Analyst Ratings Breakdown

Latest LLY, JNJ, NVO, and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/17/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,600.00
11/17/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,600.00
11/16/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,400.00 ➝ $1,550.00
11/16/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,400.00 ➝ $1,550.00
11/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B) ➝ Buy (B+)
11/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B) ➝ Buy (B+)
11/12/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy ➝ Hold
11/12/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy ➝ Hold
11/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,610.00 ➝ $1,700.00
11/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,610.00 ➝ $1,700.00
11/2/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,440.00 ➝ $1,600.00
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$99.34B6.45$13.47 per share19.74$33.87 per share7.85
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$86.46B14.73$24.04 per share56.31$42.81 per share31.62
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$86.46B14.73$24.04 per share56.31$42.81 per share31.62
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$333.65B0.52$4.46 per share8.68$7.51 per share5.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$6.6040.3123.092.7516.20%31.64%13.04%1/26/2027 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8143.9626.691.6931.90%86.76%22.03%2/3/2027 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8143.9626.691.6931.90%86.76%22.03%2/3/2027 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$3.979.7511.211.4033.99%53.52%19.49%2/3/2027 (Estimated)

Latest LLY, JNJ, NVO, and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
10/13/2026Q3 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.53$2.59+$0.06$0.09$25.38 billion$25.40 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.361.97%+5.25%81.21%64 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.50%+15.18%22.46%11 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.50%+15.18%22.46%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.812.05%+21.74%20.40%N/A

Latest LLY, JNJ, NVO, and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.48%11/13/202611/13/202612/10/2026
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.48%11/13/202611/13/202612/10/2026
10/13/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.15%11/24/202611/24/202612/8/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.44
1.02
0.74
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.54
0.84
0.64

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.75 million939.43 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.75 million939.43 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable

Recent News About These Companies

Novo Nordisk's Pipeline Momentum Meets a Widening Regulatory Front
Novo Nordisk Balances Pipeline Wins Against a Harder Road in China
Novo Nordisk: The Worst May Be Behind
Novo Nordisk (NVO) Stock May Be Undervalued On Raised 2026 Outlook
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs. Flat Revenue
Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$265.98 -6.72 (-2.46%)
As of 03:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,353.51 -29.24 (-2.11%)
As of 03:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,353.51 -29.24 (-2.11%)
As of 03:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$38.68 -0.75 (-1.90%)
As of 03:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.